Intercept Pharmaceuticals Stock News

Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In rough markets it's important to keep and eye out for overbought stocks. Finding the right timing to buy and sell stocks will always be a sought-after skill by any investor searching for that holy g

Intercept (ICPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

The stock is exploding following an announcement that it's on track to be acquired. Alfasigma is poised to buy Intercept at a price of $19 per share.

Amid a rough day on Wall Street, Intercept Pharmaceuticals (NASDAQ: ICPT ) represented a bright spot, with shares swinging up 75% before slightly adding to those gains. Catapulting the biopharmaceutic

Intercept Pharmaceuticals (NASDAQ:ICPT) Inc shares surged 79% to $18.64 in late-morning trading on Tuesday after the biopharmaceutical company specializing in rare and serious liver diseases announce

Shares of Intercept Pharmaceuticals Inc. ICPT, -0.38% were set to soar Tuesday, after the biopharmaceutical company announced an agreement to be acquired by Italy's Alfasigma S.p.A in a deal that valu

Intercept (ICPT) reports a lower net loss and beats on revenues in the second quarter. The company also updates its guidance for its lead drug, Ocaliva.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Nareg Sagherian - Executive Director, Investor Relations Jerry Durso - Pr

Intercept (ICPT) looks to restructure operations, discontinue all NASH-related investments and reduce its workforce by one-third.

Intercept's (ICPT) NDA for obeticholic acid (OCA) gets a complete response letter (CRL) from the FDA for treating pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH).

Intercept Pharmaceuticals Inc. ICPT, -1.62% on Friday said it will reduce its work force by one third as part of its plan to reach profitability in 2024. The layoffs will affect about 110 employees, b

The U.S. Food and Drug Administration on Thursday declined to grant accelerated approval for Intercept Pharmaceuticals' drug to treat a type of fatty liver disease.

Intercept Pharmaceuticals (ICPT) announces new data showing the potential of a fixed-dose combination of OCA and bezafibrate to normalize multiple biomarkers in primary biliary cholangitis.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.